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Abstract. Background/Aim: Droplet digital polymerase
chain reaction (ddPCR) is an exact method of measuring
nucleic acids. The aim of this prospective study was to
evaluate minimal residual disease (MRD) using ddPCR in
chronic myeloid leukemia (CML) patients. Patients and
Methods: Between May 2013 and November 2014, CML
patients treated with nilotinib were enrolled in our study.
BCR/ABL1 transcripts levels were evaluated using ddPCR at
the first time of complete molecular response (CMR). We
enrolled 15 patients from 7 Institutions. The treatment period
and median follow-up period were 45 months and 47 months,
respectively. Results: Patients with a high level of BCR/ABL1
transcript had a greater tendency to lose the CMR during
the follow-up period (p=0.095). In addition, patients with a
low level of BCR/ABL1 transcript showed a longer duration
of CMR compared to those with a high level (p=0.032).
Conclusion: We found that ddPCR is a sensitive method for
detecting MRD and that MRD could affect the duration of
the treatment response. 
Chronic myeloid leukemia (CML) is cytogenetically
characterized by the translocation of t(9; 22) (q34;q11.2),
which produces the BCR/ABL1 fusion oncogene (1). Since
the success of imatinib, the first targeted agent in human
history, more effective tyrosine kinase inhibitors (TKIs),
such as dasatinib and nilotinib have been introduced to the
frontline treatment of CML and show a 76-82% major
molecular response rate (2, 3). CML is now thought to be a
life-long disease with a 5-year overall survival rate>90% (4). 
Previous reports have demonstrated that achievement of an
early molecular response is a strong predictive marker of
improved outcomes (5). Therefore, the European LeukemiaNet
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guidelines recommended that the optimal response is a
percentage of BCR/ABL1 fusion transcript on the International
Scale (BCR/ABL1IS) of <10% at 3 months after initial treatment,
followed by <1% at 6 months and 0.1% at 12 months, using
quantitative real-time polymerase chain reaction (qRT-PCR) (6).
In addition, recent evidence has shown that achievement of a
deep molecular response (DMR), including MR4
(BCR/ABL1IS≤0.01%) or MR4.5 (BCR/ABL1IS≤0.0032%), is a
surrogate marker of favorable survival and treatment-free
remission (7). Currently, selected patients who achieve a DMR
can attempt to discontinue TKIs to improve their quality of life
and alleviate financial strain (8). Although qRT-PCR is
generally used for regular monitoring, additional sensitive
methods are needed to detect minimal residual disease (MRD).
Droplet digital polymerase chain reaction (ddPCR) allows
the precise quantification of nucleic acids. Due to its positive
outcomes, it has been used to detect MRD of hematologic
disorders (9). In CML, ddPCR has been validated for the
exact measurement of BCR/ABL1 fusion transcripts (10).
We hypothesized that ddPCR would be more sensitive
compared to conventional qRT-PCR for measuring
oncotranscript levels in patients with a DMR. Therefore, the
aim of this study was to evaluate MRD using ddPCR in
nilotinib-treated CML patients who firstly achieved a
complete molecular response (CMR) as assessed by qRT-
PCR. We also evaluated the relationship between ddPCR
positivity and patient prognosis. 
Patients and Methods
Patient characteristics. From May 2013 to November 2014, we
prospectively enrolled Philadelphia chromosome (Ph)-positive CML
chronic phase patients who achieved a CMR during treatment with
nilotinib. All patients were treated with nilotinib 300 mg twice daily
as the first-line target therapy. 
Inclusion and exclusion criteria were the same as those in the open-
label, multi-institutional phase 4 ENESTKorea trial (11). This study
included adult patients diagnosed as Ph-positive CML chronic phase.
The diagnosis was confirmed using cytogenetic analysis of at least 20
bone marrow metaphase cells within 6 months before enrollment. The
exclusion criteria were as follows: i) CML with atypical BCR/ABL1
transcripts (transcripts other than e13a2 or e14a2, ii) previous treatment
with myelosuppressive agents except for hydroxyurea and anagrelide,
iii) previous treatment with TKI for over two weeks, iv) previous
hematopoietic stem cell transplantation, v) previous irradiation involving
25% or more of the bone marrow tissue, vi) cytopathologically-
confirmed central nervous system involvement of CML, vii) Eastern
Cooperative Oncology Group performance status≥3 (12), viii) cardiac
abnormalities including: a) corrected QT interval≥480 milliseconds on
electrocardiogram, b) complete left bundle branch block, c) permanent
pacemaker implantation, d) congenital long QT syndrome, e) history of
tachyarrhythmia requiring treatment, f) clinically significant resting
bradycardia, g) history of acute coronary syndrome within 12 months,
and h) decompensated congestive heart failure, ix) organ dysfunction
defined by: a) total serum bilirubin levels≥1.5×the upper limit of the
normal range (ULN), b) creatinine≥1.5×ULN, c) aspartate or alanine
aminotransferase≥2.5×ULN, d) amylase or lipase≥1.5×ULN and e)
alkaline phosphatase≥2.5×ULN not directly related to the CML, x)
Active and uncontrolled malignancy other than CML, xi) uncontrolled
hypertension and/or diabetes, xii) active and uncontrolled infection, xiii)
major surgery within two weeks or incomplete recovery from the
previous surgery, xiv) congenital or acquired bleeding tendency, xv)
Impaired gastrointestinal absorption, xvi) history of small bowel
resection or bypass surgery, xvii) history of acute pancreatitis within 12
months or chronic pancreatitis, xviii) concomitant administration of
strong irreplaceable CYP3A4 inhibitors or inducers, QT prolonging
agents, or coumarin derivatives, and xix) any other uncontrolled medical
conditions that would present substantial safety risks or compromise
compliance with the study treatment. Among the patients enrolled in the
ENESTKorea trial (11), we selected patients who achieved a CMR
during the follow-up period and in whom we could evaluate the level
of BCR/ABL1 fusion transcripts using ddPCR at the time of firstly
achieving CMR. CMR was defined as an undetectable BCR/ABL1
transcript level by qRT-PCR (13). During the follow-up period, all
patients were evaluated, and BCR/ABL1 fusion transcripts were
quantified and standardized to BCR/ABL1IS by qRT-PCR performed at
the central laboratory (BML, Daejeon, South Korea) every 3 months.
This study used the protocol of qRT-PCR in ENESTKorea trial (11).
The qRT-PCR used in this study had a sensitivity of MR4.5.  
Clinical information, including patient demographics, BCR/ABL1
fusion transcript level, and adverse events (AEs), were collected
through medical record reviews at each institution.
Measurement of BCR/ABL1 fusion transcript level-Quantitative RT-
PCR analysis of the mRNA levels. The isolated total RNA was
reverse-transcribed into first-strand cDNA using SuperScript® III
First-Strand Synthesis (Invitrogen, Carlsbad, CA, USA) according
to manufacturer’s instruction. One μg of total RNA was included in
the final reaction volume of 20 μl. The reaction mixture was
incubated at 50˚C for 50 minutes, then heated to 85˚C for 5 minutes
to stop the reaction, and was then stored at –20˚C until the next
step. After reverse transcription, 2 μl from the reverse transcription
reaction was used as a template in each PCR reaction for the
BCR/ABL1 and BCR amplification. PCR was performed in a total
volume of 15 μL using the SsoAdvanced™ Universal SYBR®
Green Supermix (Bio Rad, Hercules, CA, USA) and CFX384 Real-
Time System thermocycler (Bio Rad). The amplification profile
involved denaturation at 95˚C for 30 seconds for 1 cycle and then
denaturation at 95˚C for 15 seconds and one step of annealing and
elongation at 65˚C for 30 seconds for 45 cycles. Following
completion of the PCR, the amplification pattern of BCR/ABL1 and
BCR was checked using a melting curve analysis. The threshold
cycle number (CT) of each sample was used to determine the copy
number and was compared to a corresponding standard curve
generated with 7 different copy numbers (from 106 to 100 copies)
for each recombinant plasmid, including the BCR or BCR/ABL1
amplified region. The primer set for BCR/ABL1 was 5’-
GATGCTGACCAACTCGTGTG-3’ for the forward and 5’-
AACGAAAAGGTTGGGGTCAT-3’ for the reverse. The primer set
for BCR was 5’-TTCTGGACCACCTGAAAAGG-3’ for the
forward and 5’-TGCTCTGTCTCTTGCTGTCC-3’ for the reverse.
Droplet generation. ddPCR was performed in a total volume of 20 μl
containing 10 μl EvaGreen supermix (2×, Bio-Rad Laboratories), each
primer set (final concentration of 150 nM), DNase/RNase-free sterile
water, and a variable volume of diluted cDNA (40, 20, or 5 ng) to
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achieve a higher sensitivity and to define the threshold. Primer
sequences are as follows; BCR forward primer: 5’-TTC TGG ACC
ACC TGA AAA GG-3’; BCR reverse primer: 5’-TGC TCT GTC TCT
TGC TGT CC-3’; BCR/ABL1 forward primer: 5’-GAT GCT GAC
CAA CTC GTG TG-3’; BCR/ABL1 reverse primer: 5’-AAC GAA
AAG GTT GGG GTC AT-3’. Each ddPCR mixture was loaded into
each sample well of a DG8 droplet generator cartridge (Bio-Rad
Laboratories), followed by the loading of 70 μl droplet generation oil
for EvaGreen (Bio-Rad Laboratories) into each oil well of the DG8
cartridge. The cartridge was placed inside a QX200 droplet generator
(Bio-Rad Laboratories). When droplet generation was completed,
approximately 20,000 droplets were generated in each droplet well.
Droplets in each droplet well were transferred to a 96-well PCR plate
(Bio-Rad Laboratories) and were sealed using a PX1 PCR plate sealer
(Bio-Rad Laboratories) for 5 seconds at 180˚C before thermal cycling.
The PCR plate was placed in a deep-well C1000 Touch thermal cycler
(Bio-Rad Laboratories) for amplification. Thermal cycling conditions
were: i) 5 minutes at 95˚C, ii) 40 cycles of denaturation for 30 seconds
at 95˚C and iii) annealing/extension for 1 minute at 58˚C, and three
final steps iv) at 4˚C for 5 minutes, v) 90˚C for 5 minutes, and vi) 4˚C
infinite hold. All PCR steps were conducted with a change of 2˚C/s.
A no template control and a positive control (cDNA synthesized from
K562 total RNA) were included in each assay.
ddPCR. Following thermal cycling, the PCR plate including the
droplets was loaded onto the QX200 droplet reader (Bio-Rad
Laboratories), which identified the fluorescence intensity of each
droplet for EvaGreen fluorophore, using a multi-pixel photon
counter. This detector reads the droplets to identify those that do (+)
or do not (–) contain a target gene by plotting fluorescence droplet-
by-droplet. We determined droplets to be positive ones only for
samples whose fluorescence levels differed significantly from the
back-ground fluorescence level. We used QuantaSoft software
version 1.7.4 (Bio-Rad Laboratories) to determine the concentration
of the target gene in copies/μl.
Statistical analysis. Comparisons of categorical variables were
performed using Fisher’s exact tests. The Kaplan-Meier method was
used to analyze the period of treatment response. The duration of
CMR was defined as the period of undetectable BCR/ABL1
transcript (BCR/ABL1IS=0%) by qRT-PCR. The duration of MR4.5
was defined as the period from no detection of BCR/ALB1 (i.e., the
day ddPCR was performed) firstly to the loss of MR4.5
(BCR/ABL1IS=0.0032%) by qRT-PCR. The cut-off value of
BCR/ALB1 transcript level was the median value (3.6 copies/20 μL)
of the total level of BCR/ABL1 transcripts measured using 40, 20,
or 5ng of RNA (Table II).
Ethical considerations. The study protocol was reviewed and
approved by the Institutional Review Board of each of the 7
hospitals and was in accordance with principles established
by the Declaration of Helsinki for biomedical research (14).
Informed consent was obtained from all patients for being
included in the study.
Results
Patient characteristics. Between May 2013 and November
2014, 15 patients from 7 institutions who met the inclusion
criteria were enrolled in this study (Figure 1 and Table I). The
median follow-up period for a total of 110 patients was 22.7
months (range=0.1-54.2 months), and for the 80 patients who
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Figure 1. CONSORT flow diagram. CMR: Complete molecular response; ddPCR: droplet digital polymerase chain reaction.
did not achieve CMR, it was 22.5 months (range=0.1-37.0
months), respectively. The median follow-up period for the
15 patients who were included in this study was 47 months
(range=39-61 months). All patients received nilotinib at a
starting dose of 300 mg twice daily. Median patient age was
56 years (range=38-83 years). Ten (66.7%) and five (33.3%)
patients were male and female, respectively. 
ddPCR measurement. We measured the levels of BCR/ABL1
and BCR transcripts using ddPCR three times when CMR
was firstly achieved, as verified by qRT-PCR (Table II). The
median values of total BCR/ABL1 and BCR transcript levels
were 3.6 copies/20 μl (range=1.2-6.8 copies/20 μl) and
15,758 copies/20 μl (range=1802-34140 copies/20 μl),
respectively. 
ddPCR results and treatment outcome. The median treatment
and follow-up periods for the 15 patients were 45 months
(range=37-55 months) and 47 months (range=39-61 months),
respectively. Except for one patient who switched to imatinib
in vivo 33: 2273-2280 (2019)
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Table I. Baseline patient characteristics (n=15).
Patient             Gender             Age (years)           Treatment period (months)           Change to other drug         Cause of change            Loss of MR4.5
1                        Male                      51                                       58                                     Yes (imatinib)                   AE (angina)                         Yes
2                        Male                      58                                       43                                              No                                     -                                   No
3                        Male                      43                                       53                                              No                                     -                                  Yes
4                        Male                      47                                       41                                              No                                     -                                   No
5                      Female                     52                                       48                                              No                                     -                                   No
6                        Male                      63                                       45                                              No                                     -                                   No
7                        Male                      77                                       45                                              No                                     -                                   No
8                      Female                     44                                       43                                              No                                     -                                   No
9                        Male                      54                                       41                                              No                                     -                                   No
10                    Female                     38                                       42                                              No                                     -                                   No
11                      Male                      83                                       39                                              No                                     -                                   No
12                      Male                      64                                       54                                              No                                     -                                   No
13                    Female                     58                                       44                                              No                                     -                                   No
14                    Female                     56                                       47                                              No                                     -                                   No
15                      Male                      64                                       45                                              No                                     -                                   No
AE: Adverse event; MR4.5: molecular response at 4.5-log reduction.
Table II. BCR/ABL1 transcript levels using ddPCR at IS 0%.
Patient                    BCR level                   Total BCR/ABL1 level                                                    BCR/ABL1 level (copies/20 μl)
                           (copies/20 μl)                        (copies/20 μl)
                                                                                                                             Input RNA (40 ng)          Input RNA (20 ng)              Input RNA (5 ng)
1                               15,758                                        6.6                                                  4.0                                     1.2                                       1.4
2                               18,836                                        2.2                                                  0.0                                     0.0                                       2.2
3                                 4,098                                        3.8                                                  0.0                                     2.6                                       1.2
4                               10,728                                        3.6                                                  3.6                                     0.0                                       0.0
5                               22,382                                        2.4                                                  0.0                                     2.4                                       0.0
6                                 2,434                                        4.0                                                  1.2                                     0.0                                       2.8
7                               11,196                                        1.2                                                  1.2                                     0.0                                       0.0
8                               11,860                                        6.8                                                  1.2                                     1.2                                       4.4
9                               26,262                                        6.4                                                  1.2                                     2.4                                       2.8
10                             31,024                                        2.6                                                  1.2                                     0.0                                       1.4
11                             18,294                                        3.6                                                  2.4                                     1.2                                       0.0
12                             34,140                                        3.6                                                  1.2                                     2.4                                       0.0
13                               1,802                                        2.6                                                  0.0                                     1.2                                       1.4
14                               9,908                                        1.2                                                  1.2                                     0.0                                       0.0
15                             25,720                                        2.6                                                  1.2                                     0.0                                       1.4
ddPCR: Droplet digital polymerase chain reaction; IS: International Scale.
37 months after initiation of nilotinib due to a nilotinib-induced
cardiovascular event, 14 patients were treated with nilotinib
continuously. During the follow-up period, all patients
maintained a major molecular response (BCR/ABL1IS≤0.1%).
Among 15 patients, 2 patients lost CMR during the follow-up
period. One patient lost CMR after sustaining it over 21.3
months, and 0.002% of BCR/ABL1 was detected by qRT-PCR.
The other patient lost CMR, and 0.012% of BCR/ABL1 was
detected after sustaining it for 20.5 months. However, they did
not lose MMR during the last follow-up period (9 months for
one patient and 8 months for the other patient after the loss of
CMR).
In subsequent analyses, we used the median value of total
BCR/ABL1 transcript levels (3.6 copies/20 μl) as a cut-off
value. Although patients with a high level (>3.6 copies/20 μl)
of BCR/ABL1 transcripts had a tendency to lose the CMR
during the follow-up period, there was no significant
difference in CMR loss between patients with a low level
(0/10, 0%) versus a high level (2/5, 40%) (p=0.095; Table III).
CMR duration was prolonged in patients with a low level of
BCR/ABL1 transcripts, as measured by ddPCR (rate of
sustained CMR at 2 years: 100% for low level versus 37.5%
for high level, p=0.032; Figure 2A). However, there was no
significant difference between groups from the day of the first
CMR to the day of MR4.5 loss (rate of sustained MR4.5 at 2
years:100% for low level versus 75.0% for high level,
p=0.186; Figure 2B).
Discussion
MRD is considered very important in various cancers
because a low or negative MRD after treatment is associated
with a longer response duration and survival (15-17), and the
achievement of a DMR predicts a better clinical outcome in
CML patients (18). Due to the remarkable results of
withdrawal clinical studies (i.e., STIM and TWISTER
studies), the appropriate selection of patients with a “true”
CMR is important for predicting the success of treatment-
free remission (19, 20).
Currently, qRT-PCR is the primary method for monitoring
the TKI response and MRD and for predicting early relapse
(6, 21). Although qRT-PCR is relatively sensitive, it has
several limitations due to its poor standardization and labor-
intensiveness (22). To overcome these limitations, recent
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Figure 2. Kaplan Meier graphs. (A) The duration of complete molecular response depending on BCR/ABL1 transcript level (median: 3.6 copies/20
μL) as measured by ddPCR. (B) Period of no BCR/ABL1 detection using qRT-PCR to loss of MR4.5. IS: International Scale; MR4.5: molecular
response at 4.5-log reduction; ddPCR: droplet digital polymerase chain reaction; qRT-PCR: quantitative real-time polymerase chain reaction. 
Table III. Tendency for loss of CMR during the follow-up period.
                                                                                  Low BCR/ABL1 level by                           High BCR/ABL1 level by                            p-Value
                                                                                   ddPCR at time of CMR                             ddPCR at time of CMR 
                                                                                       (<3.6 copies/20 μl)                                      (≥3.6 copies/20 μl)
Loss of CMR by qRT-PCR                                                    0 (0%)                                                           2 (40%)                                             0.095
No loss of CMR by qRT-PCR                                             10 (100%)                                                      3 (60%)                                                 
CMR: Complete molecular response; ddPCR: droplet digital polymerase chain reaction; qRT-PCR: quantitative real-time polymerase chain reaction. 
emerging technologies, such as next-generation sequencing,
next-generation flow, and ddPCR, have been applied for
precision medicine (23, 24). Among these, ddPCR is an
advanced method with results that strongly correlate with
those of qRT-PCR (25, 26). ddPCR enables the measurement
of absolute copy numbers without requiring a reference
standard curve (9, 10, 27). Furthermore, it can detect nucleic
acids with a sensitivity exceeding 10–6 and is less influenced
by inhibitory substances, non-target RNA, and nonspecific
amplification (10, 27). Because of these advantages, ddPCR
has been used to evaluate circulating tumor DNA, mutations,
and tumor burden in cancer research (28). ddPCR has also
been used to detect MRD and predict prognosis in
hematologic malignancy (9, 25). Therefore, ddPCR could be
an optimal alternative modality for qRT-PCR; however,
disadvantages of ddPCR, including its high cost, time-
intensiveness, and limited data in the clinical setting, must
be solved to allow its wider use (29).
Our results indicate that ddPCR could be a sensitive tool
for detecting MRD as a complement to qRT-PCR.
BCR/ABL1 transcripts were detected in all patients by
ddPCR even though a CMR state (BCR/ABL1IS=0%) was
verified by qRT-PCR. In addition, we noted that the duration
of CMR differed significantly depending on MRD, as
detected by ddPCR at the time when CMR was firstly
achieved. This finding suggests that a low MRD is an
important factor for maintaining longer remission periods,
consistent with the results of previous studies (18). However,
because all our patients maintained a major molecular
response during their treatment with TKIs, it is questionable
whether an elevated BCR/ABL1 transcript level detected by
ddPCR is clinically meaningful as a treatment failure (6).
Additionally, because of the superior treatment response to
nilotinib, with an approximately 80% rate of complete
cytogenetic response, all patients might maintain an optimal
response during the follow-up period (30). Therefore, for an
evaluation of long-term outcomes, further follow-up might
be needed.
Additional limitations of this study were that we could not
routinely use ddPCR for response monitoring every 3
months. Because ddPCR is not yet widely commercialized,
frequent use of ddPCR was limited. In addition, some
patients did not show homogeneous results according to the
input RNA, which is also another limitation. The
standardization of the quantitative measurement of
BCR/ABL1 by ddPCR has not yet been well-established.
Therefore, there has been a concerted effort to obtain precise
results with less false-positive droplets (e.g. using an
adequate volume of cDNA) (26). Nevertheless, a previous
study has shown that the false-positive rate can be 2% even
when healthy donors are used (31). Therefore, further
standardization and validation of the protocol are needed for
a higher sensitivity of ddPCR. 
Another limitation of our study was that sample size was
small despite this being a multi-institution study. Therefore,
a large-scale study is needed to confirm these results.
Despite these limitations, to the best of our knowledge, this
is the first study reporting a difference in outcomes
depending on BCR/ABL1 transcript level measured by
ddPCR in CML patients with a CMR state. 
In conclusion, we demonstrated the sensitivity of ddPCR
for detecting MRD at the time of undetectable BCR/ABL1
transcripts, as measured by qRT-PCR in CML patients.
Additionally, the duration of CMR differed significantly
depending on MRD at the time when the CMR was firstly
achieved. Future large-scale trials and rigorous validation of
the ddPCR are needed to widely use ddPCR for monitoring
treatment response and for detecting MRD. 
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